The
India CRO market industry is projected to grow from USD 0.7 Billion in 2023 to
USD 1.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of
7.50% during the forecast period (2023 - 2032).
The
India
Contract Research Organization (CRO) market in India showcases steady
growth amidst global trends. With a burgeoning pharmaceutical and biotechnology
sector, India emerges as a prominent hub for outsourced research services.
Factors such as cost-effectiveness, skilled workforce, and regulatory compliance
contribute to India's attractiveness for CRO partnerships. Pharmaceutical
giants and emerging biotech startups alike leverage India's robust
infrastructure and diverse talent pool for clinical trials, drug development,
and regulatory submissions. Government initiatives promoting research and
development further bolster the CRO landscape. Despite challenges like quality
control and intellectual property concerns, India remains a pivotal player in
the global CRO market, poised for sustained expansion.
The
Clinical Research Organizations (CRO) market in India is experiencing
significant growth, fueled by the country's thriving pharmaceutical and
biotechnology sectors. India has emerged as a preferred destination for
clinical trials and research due to its large pool of diverse patient
populations, skilled healthcare professionals, and cost-effective services.
Clinical
Research Organizations in India offer a comprehensive range of services
encompassing clinical trial management, regulatory compliance, data management,
pharmacovigilance, and bioanalytics. These CROs provide end-to-end solutions to
pharmaceutical, biotech, and medical device companies, helping them navigate
the complex landscape of drug development and regulatory approval processes.
With
a strong emphasis on quality, compliance, and adherence to international
standards, Clinical Research Organizations in India have gained recognition for
their expertise and reliability in delivering high-quality clinical research
services. They leverage cutting-edge technology, robust infrastructure, and
experienced personnel to ensure efficient and timely execution of clinical
trials and studies.
The
competitive landscape of the India CRO market is characterized by both domestic
players and multinational companies establishing their presence in the region.
This competition drives innovation and enhances the overall capabilities of the
industry, offering clients a wide array of options to choose from for their
research needs.
The
India CRO market has been segmented on the basis of end users, service types,
therapeutic application, and lastly region. Based on end users, this market has
been segmented into academic institutes, medical devices companies, and
pharmaceutical/biopharmaceutical companies. On the basis of services, the
market has been segmented into clinical trials, process development, product
development, post-marketing surveillance, quality monitoring, and others. The therapeutic application-based
segmentation of India CRO market segments the market into cardiovascular,
nephrology, neurology, oncology, and urology, and others.
The regional segmentation
of India CRO market segments the market into different geographic regions and
states. South India and West India hold
the major share of the Indian CRO market. However, due to the concentration of regulatory authority, of late
the CRO industry is shifting to North
India. Also, the costs are lower in North
India due to more unemployment and cheaper land rates in small towns. In North
India, the genetic pool is more diverse.
Key
Players
The
key players in the India CRO market include Ace Biomed Pvt. Ltd. (Mumbai),
Actimus Biosciences Pvt. Ltd. (Visakhapatnam), Actis Biologics Pvt Ltd., Alkem
Laboratories Ltd., CliniRX Tangent Research (Mumbai), Clininvent (Mumbai),
Ecron Acunova (Chennai), GVK Bio (Hyderabad), Pharmaceutical Product
Development (United States of America - USA), Quintiles IMS Holdings, Inc.
(USA), and Siro Clinpharm (Thane).
Latest
Industry News
·
GSK
has signed an R&D agreement with
India-based CRO Syngene according to which, both companies will work on
accelerating the discovery of new drug candidates using Syngene's discovery
services platforms. 26 MAR 2018
·
With
a new office in Bangalore, PSI CRO is
expanding its operations in India. 6 AUG 2018
For More Information, Please Visit @ Market Research Future
Comments
Post a Comment